Clinical Trial

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Recruiting Phase 1/2

Summary

This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC. The goal is to explore new ways to treat these cancers by helping immune cells target and destroy cancer cells. The study will evaluate the use of REGN15505 when administered alone, in combination with cemiplimab, or in combination with REGN4336 for: * Any side effects of study drugs * How well the study drugs work * How much REGN15505, cemiplimab, and REGN4336 are in the blood at different times * If the body makes antibodies to REGN15505 or REGN4336, which may mean the study drugs will not work as well as expected * What is the best dose of REGN15505 when administered alone and with cemiplimab and the best dose of REGN15505 and REGN4336 when used in combination

Protocol Amendment History 4 changes

critical Recruitment opened 2026-08-06

notable Trial sites expanded: 0 -> 4 locations 2026-08-06

notable Primary completion pushed: 2030-09-20 -> 2030-10-27 2026-08-06

minor Completion pushed: 2030-09-20 -> 2030-10-27 2026-08-06

Trial Details

NCT Number	NCT07594106
Lead Sponsor	Regeneron Pharmaceuticals
Conditions	Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Enrollment	265 participants
Start Date	2026-07-20
Primary Completion	2030-10-27 (estimated)
Study Completion	2030-10-27 (estimated)
Updated on ClinicalTrials.gov	2026-08-05